For people living with depression that does not improve with standard treatment, daily life can become exhausting. When months or years of medication and therapy bring little relief, both individuals and families often feel stuck, frustrated, and blamed by a system that quietly assumes improvement should have happened by now.
This is the reality of difficult to treat depression. The term does not imply resistance, failure, or lack of effort. It simply describes a situation where, despite careful treatment, a significant burden of symptoms and functional impairment remains. Seen this way, difficult to treat depression invites a broader clinical lens, one that includes physical health, long term stress exposure, trauma history, and biological processes that are not routinely assessed in everyday psychiatric care.
In my clinical and research work, I have focused on understanding why some people do not benefit from conventional antidepressant approaches. In a recent paper, I proposed that within difficult to treat depression there may be a distinct biological profile characterised by low grade inflammation. In this group, ongoing symptoms may reflect a mismatch between the underlying biology and treatments that primarily target neurotransmitters such as serotonin.
A growing body of evidence suggests that a substantial subgroup of individuals with depression exhibits elevated markers of systemic inflammation. One of the most accessible markers is high sensitivity C reactive protein (hs CRP), which, when considered alongside other cytokines, allows for the delineation of a more informative and clinically interpretable immunological profile. In this context, hs CRP can be used as an initial screening tool, while the measurement of pro inflammatory cytokines enables a more precise phenotyping of the inflamed subgroup. This approach has no intrinsic diagnostic value on its own, but gains significance within an integrated assessment of depression that also considers clinical features such as anergia, psychomotor slowing, and anhedonia, alongside metabolic comorbidities, chronic stress factors, and a history of trauma.
The implication is straightforward. If inflammation is playing a central role, treatments that only target monoamines may struggle to work. This is not because the person is doing something wrong, but because the main driver of their symptoms is not being addressed.
What makes this approach particularly relevant for real world practice is its practicality. Inflammation can often be screened using routine blood tests that are already familiar in general medicine. When elevated inflammatory markers are identified, they can be interpreted alongside well known confounders such as obesity, smoking, metabolic conditions, infections, and medication effects. This does not replace clinical judgement. It strengthens it.
When inflammation appears to be part of the picture, it opens up additional treatment options. Research suggests that some people with elevated inflammatory markers may benefit from adding anti inflammatory agents to antidepressant treatment. Other approaches under investigation include medications that influence immune signalling in the brain, neuromodulation techniques that affect inflammatory pathways, and lifestyle interventions with measurable biological effects.
Physical activity, for example, is not only beneficial for mood and motivation. Regular exercise has been associated with reductions in inflammatory markers and improvements in immune balance. Psychotherapy also appears to have biological effects, with some studies suggesting changes in inflammatory activity that persist beyond the end of treatment. These findings remind us that psychological and biological processes are deeply intertwined rather than competing explanations.
For people who have lived through repeated treatment attempts without improvement, this framework can be deeply validating. Persistent depression does not have to mean personal failure or an unchangeable condition. It may simply mean that the treatment approach has not yet matched the biology sustaining the symptoms.
For families, this perspective can offer relief from years of confusion and guilt. It provides a rational explanation for why improvement has been so hard to achieve and points towards new possibilities rather than resignation. Tracking inflammatory markers over time may also offer a more objective way to judge whether a treatment is helping, both clinically and biologically.
At a service level, this kind of stratified approach does not need to be expensive or elitist. Basic inflammatory screening is already widely available and could be integrated into community mental health care. More specialised assessments can be reserved for selected cases, supported by clear protocols and appropriate training. The goal is not to medicalise distress further, but to reduce trial and error and bring greater precision to care.
The idea of an inflamed subtype of difficult to treat depression is not presented as a fixed label or final answer. It is a testable, evolving framework that encourages clinicians to look beyond symptoms alone and consider whether underlying biology may be guiding outcomes. For patients and families, the message is simple. When depression persists, it may not be because treatment has failed, but because the right target has not yet been identified.
Walter Paganin, PhD is a psychiatrist and researcher based in Rome. His work focuses on chronic mood disorders and the development of integrated, patient-centred treatment models.
